Results 81 to 90 of about 22,913 (185)

Summarizing the Experiences of Individuals Who Have Obesity or Larger Bodies Seeking Fertility Care: A Scoping Review

Obesity Reviews, EarlyView.
ABSTRACT Females who have larger bodies or obesity may be at an increased risk for experiencing infertility. Problematically, both weight or body size and infertility are stigmatized, harming quality of care. We conducted a scoping review to understand the lived experiences of patients who may be subjected to intersecting stigmas of weight and ...
Brooke J. Hebert, Hanna Randhawa, Virginie Blanchette, Kristi B. Adamo, Angela Alberga, Jean‐Patrice Baillargeon, Marilou Côté, Julia Craig, Ariadne Daniel, Liz Dennett, Nicola Heslehurst, Sarah Nutter, Ian Patton, Helena Piccinini‐Vallis, Ximena Ramos Salas, Katie Wadden, Taniya S. Nagpal   +16 more
wiley   +1 more source

Ovulation rates in a stair-step protocol with Letrozole vs clomiphene citrate in patients with polycystic ovarian syndrome

Contraception and Reproductive Medicine, 2019
Purpose To compare ovulation rates between Letrozole and Clomiphene Citrate (CC) using a stair-step protocol to achieve ovulation induction in women with Polycystic Ovarian Syndrome (PCOS). Methods This is a retrospective cohort of predominantly Hispanic
S. Thomas, I. Woo, J. Ho, T. Jones, R. Paulson, K. Chung, K. Bendikson   +6 more
doaj   +1 more source

Long-term efficacy and safety of letrozole for the adjuvant treatment of early breast cancer in postmenopausal women: a review

, 2009
Alain MonnierInstitut Régional Fédératif du Cancer (IFRC), Centre Hospitalier Belfort-Montbéliard, Montbéliard, FranceAbstract: Aromatase inhibitors (AIs) are becoming more widely used than tamoxifen
Alain Monnier
core  

Exploring lifestyle management in polycystic ovary syndrome through implementation frameworks

Experimental Physiology, EarlyView.
Abstract Polyendocrine metabolic ovarian syndrome [PMOS; previously known as polycystic ovary syndrome (PCOS)] is an endocrine condition affecting 10%–13% of women of reproductive age, with cardiometabolic, reproductive and psychological features. The PMOS guidelines have established recommendations for its management, which can include pharmacological,
Margaret McGowan, Stephanie Cowan, Chau Thien Tay, Lisa J. Moran, Ashley H. Ng   +4 more
wiley   +1 more source

GP88 (PC-Cell Derived Growth Factor, progranulin) stimulates proliferation and confers letrozole resistance to aromatase overexpressing breast cancer cells

BMC Cancer, 2011
Background Aromatase inhibitors (AI) that inhibit breast cancer cell growth by blocking estrogen synthesis have become the treatment of choice for post-menopausal women with estrogen receptor positive (ER+) breast cancer.
Sabnis Gauri, Brodie Angela, Abrhale Tesfom, Macedo Luciana, Tian Changsheng, Yue Binbin, Serrero Ginette   +6 more
doaj   +1 more source

Preclinical modeling of endocrine response: a combination therapy approach with the ERβ agonist, diarryl propionitrile and letrozole restores sensitivity to letrozole-resistant breast cancer cells.

, 2009
Abstract #17 The majority of breast cancer patients are postmenopausal women with estrogen receptor-positive (ER+) tumors. Approximately 66% of breast carcinomas contain aromatase. Aromatase inhibitors are proving to be more effective than
SR Saha, RP Perla, RR Tekmal, P Veerapaneni, NB Kirma, HB Nair, DB Evans, B Santhamma, AH Brodie, AK Joseph, R Jayarajan   +10 more
core   +1 more source

De‐Escalation of Neoadjuvant Treatment for HER2‐Positive Breast Cancer

International Journal of Cancer, Volume 159, Issue 10, Page 2393-2402, 15 November 2026.
ABSTRACT With improved prognosis in early HER2‐positive breast cancer, safely de‐escalating treatment is increasingly investigated to minimize overtreatment. This article focuses on neoadjuvant de‐escalation strategies for HER2‐positive breast cancer.
Yiyin Ma, Dedian Chen, Sheng Huang
wiley   +1 more source

Efficacy and Safety of Controlled Ovarian Stimulation With or Without Letrozole Co-administration for Fertility Preservation: A Systematic Review and Meta-Analysis

Frontiers in Oncology, 2020
Background: The co-administration of letrozole during controlled ovarian stimulation (COS) with gonadotropins is used to limit the potentially harmful effects of a supra-physiological rise in estrogen levels on hormone-sensitive cancers.
Benedetta Bonardi, Benedetta Bonardi, Claudia Massarotti, Marco Bruzzone, Oranite Goldrat, Giorgia Mangili, Paola Anserini, Stefano Spinaci, Luca Arecco, Luca Arecco, Lucia Del Mastro, Lucia Del Mastro, Marcello Ceppi, Isabelle Demeestere, Isabelle Demeestere, Matteo Lambertini, Matteo Lambertini   +16 more
doaj   +1 more source

Letrozole removal resulted in fasting blood glucose levels and insulin tolerance similar to placebo mice.

, 2019
Fasting blood glucose (A) and insulin levels (B) were measured for placebo and letrozole-treated mice before (Pre; week 5) and after (Post; week 12) pellet removal (n = 8 placebo, n = 8 letrozole).
Bryan S. Ho (7444598), Lillian Sau (6468299), Scott T. Kelley (7444601), Varykina G. Thackray (7444604), Pablo Arroyo (316123)   +4 more
core   +1 more source

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, Volume 20, Issue 11, Page 2784-2804, November 2026.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source